Jean-Luc Vachiéry is an expert in Cardiology at Erasmus Hospital (Belgium). As of July 2026, ScienceLeadR ranks Jean-Luc Vachiéry in the top 1% of experts worldwide for Hypertension and Hypertension, Pulmonary. Jean-Luc Vachiéry has authored 296 publications, the most recent in 2026, and is an investigator in 12 clinical trials. SLR score: 1,098 (community average: 125). How the SLR is computed.

LeadR Profile

Jean-Luc Vachiéry Erasmus Hospital Belgium
1 098 ScienceLeadR Reputation 1098
Network Map

Cardiology

Subspecialties: Pulmonology - Transplantation

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026

Source: PubMed

Université Libre de Bruxelles

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 296

Citations

Citations: 40 933 1st author: 28 Last author: 56 Unique author: 6


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study.
PMID 42520828 — epoprostenol, hypertension, safety, vascular resistance, disease progression, pulmonary artery, arteries, drug-related side effects and adverse reactions, pulmonary arterial hypertension, therapeutics
Lancet Top journal20260
Acetazolamide, residual congestion and clinical outcomes in acute heart failure - a prespecified analysis of the ADVOR trial.
PMID 42523039 — acetazolamide, mortality, heart failure, heart, cardiology, therapeutics, prognosis
Acta Cardiol20262
Implementation opportunities for sodium-glucose Co-transporter-2 inhibitors in the Belgian heart failure landscape.
PMID 42483979 — heart failure, heart, symporters, cardiology
Acta Cardiol20261
Diagnostic and management dilemmas in pulmonary hypertension.
PMID 42128486 — hypertension, hypertension, pulmonary, neurofibromatosis 1
Eur Respir Rev20260
Circulating Biomarker Results From a Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension.
PMID 42104009 — hypertension, critical care, biomarkers, pulmonary arterial hypertension
Am J Respir Crit Care Med20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 7
N/A 2
Phase 1 1
Phase 2 1
Phase 4 1

By status:

Completed 9
Active not recruiting 1
No longer available 1
Unknown 1

By type:

Interventional 11
Expanded Access 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 9

Main Topics

LeadR Networks

Main global connection map